AZ reports data from immunotherapy trial

As companies with lung cancer immunotherapies process the small level detail they received on the outcome of August's PBAC meeting at which the committee considered simplifying their reimbursement, AstraZeneca has announced new and positive results from its yet-to-be-listed IMFINZI (durvalumab). …